Akebia Therapeutics, Inc.
AKBA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $166 | $137 | $113 | $52 |
| Short-Term Investments | $0 | $0 | $0 | $0 |
| Receivables | $66 | $73 | $62 | $34 |
| Inventory | $19 | $17 | $20 | $16 |
| Other Curr. Assets | $7 | $8 | $9 | $11 |
| Total Curr. Assets | $258 | $235 | $204 | $114 |
| Property Plant & Equip (Net) | $6 | $8 | $9 | $10 |
| Goodwill | $59 | $59 | $59 | $59 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $2 | $2 | $0 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $40 | $43 | $37 | $37 |
| Total NC Assets | $106 | $111 | $106 | $107 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $364 | $346 | $310 | $221 |
| Liabilities | – | – | – | – |
| Payables | $10 | $12 | $13 | $15 |
| Short-Term Debt | $5 | $6 | $6 | $10 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $4 | $6 | $1 | $0 |
| Other Curr. Liab. | $114 | $96 | $72 | $56 |
| Total Curr. Liab. | $133 | $119 | $91 | $81 |
| LT Debt | $48 | $48 | $49 | $179 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $142 | $150 | $146 | $10 |
| Total NC Liab. | $189 | $198 | $194 | $189 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $5 | $6 | $8 | $9 |
| Total Liabilities | $323 | $316 | $286 | $270 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$1,671 | -$1,672 | -$1,672 | -$1,678 |
| AOCI | $0 | $0 | $0 | $0 |
| Other Equity | $1,713 | $1,701 | $1,697 | $1,629 |
| Total Equity | $42 | $29 | $25 | -$49 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $364 | $346 | $310 | $221 |
| Net Debt | -$114 | -$84 | -$59 | $137 |